ECCO 2025
19-22 February 2025
Berlin, Germany
Fernanda Schreiber and Elaine Driver attending and presenting
At Microbiotica, we are translating clinic-led microbiome science into transformative life-changing medicines.
About Us
Building a clinical-stage biopharmaceutical company supported by leaders in precision microbiome science and medicine, and a strong syndicate of investors.
Pipeline
Advancing our pipeline of clinic-ready defined live biotherapeutic products, with known mechanisms of action, for immuno-oncology and inflammatory bowel disease.
Platform
Leveraging our clinic-led discovery platform to enable precise identification of bacteria linked to patient outcomes and targeting of specific patient populations.
News
- Microbiotica Announces First Patient Dosed in its Phase 1b Trial (COMPOSER-1) of MB310, a Precision Microbiome Medicine, in Ulcerative Colitis Patients 13 November 2024
- Microbiotica Announces First Patient Dosed in its International Phase 1b Trial, MELODY-1 of MB097 Precision Microbiome Co-Therapy in Advanced Melanoma 7 October 2024
Events
Keystone. Human Microbiome: Diversity, Selection and Adaptation
18-21 February 2025
Fairmont Banff Springs, Banff, AB, CanadaTrevor Lawley and Mat Robinson attending and presenting
AACR IO
23-26 February 2025
JW Marriott Los Angeles L.A. LiveGhaith Bakdash attending and presenting
Microbiotica is a clinic-ready biopharmaceutical company developing a pipeline of orally-delivered live biotherapeutic products (LBPs) composed of highly-defined bacterial strains for therapeutic applications in immuno-oncology (IO) and inflammatory bowel disease (IBD).
